Chemistry:LY305
From HandWiki
Short description: Chemical compound
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C14H17ClN2O2 |
| Molar mass | 280.75 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
LY305 is a transdermally bioavailable selective androgen receptor modulator (SARM) developed by Eli Lilly for the treatment of osteoporosis in men. Its chemical structure includes N-arylhydroxyalkyl. A phase one trial found promising results.[1][2][3]
See also
References
- ↑ Krishnan, V.; Patel, N. J.; Mackrell, J. G.; Sweetana, S. A.; Bullock, H.; Ma, Y. L.; Waterhouse, T. H.; Yaden, B. C. et al. (2018). "Development of a selective androgen receptor modulator for transdermal use in hypogonadal patients". Andrology 6 (3): 455–464. doi:10.1111/andr.12479.
- ↑ Christiansen, Andrew R.; Lipshultz, Larry I.; Hotaling, James M.; Pastuszak, Alexander W. (March 2020). "Selective androgen receptor modulators: the future of androgen therapy?". Translational Andrology and Urology 9 (Suppl 2): S135–S148. doi:10.21037/tau.2019.11.02. ISSN 2223-4683. PMID 32257854.
- ↑ Mohler ML, Sikdar A, Ponnusamy S, Hwang DJ, He Y, Miller DD, Narayanan R. An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer. Int J Mol Sci. 2021 Feb 20;22(4):2124. doi:10.3390/ijms22042124 PMID 33672769
 |  |
